Oncolytics Biotech Meets Primary Endpoint for First Part of Phase 2 Pancreatic Cancer Clinical Trial

Oncolytics Biotech Inc. ONCY today announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN in combination with gemcitabine (Gemzar ) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC). The Principal Investigator is Dr. Monica Mita of the CTRC.